EXAS Exact Sciences Corp

Price (delayed)

$131.00

Market cap

$22.15B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.61

Enterprise value

$22.39B

Sector: Healthcare
Industry: Diagnostics & Research

Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first ...

Highlights

EXAS's gross profit has surged by 72% year-on-year and by 14% since the previous quarter
EXAS's revenue has surged by 70% year-on-year and by 13% since the previous quarter
The company's quick ratio has surged by 88% YoY but it fell by 39% QoQ
Exact Sciences's EPS has plunged by 163% from the previous quarter
The company's net income has shrunk by 154% QoQ

Key stats

What are the main financial stats of EXAS
Market
Shares outstanding
169.09M
Market cap
$22.15B
Enterprise value
$22.39B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.98
Price to sales (P/S)
13.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.01
Earnings
Revenue
$1.49B
EBIT
-$761.12M
EBITDA
-$582.04M
Free cash flow
$72.13M
Per share
EPS
-$5.61
Free cash flow per share
$0.48
Book value per share
$18.77
Revenue per share
$9.87
TBVPS
$18.78
Balance sheet
Total assets
$4.93B
Total liabilities
$2.1B
Debt
$1.73B
Equity
$2.82B
Working capital
$1.62B
Liquidity
Debt to equity
0.61
Current ratio
3.82
Quick ratio
3.6
Net debt/EBITDA
-0.41
Margins
EBITDA margin
-39%
Gross margin
76.2%
Net margin
-56.9%
Operating margin
-51.5%
Efficiency
Return on assets
-18.6%
Return on equity
-33.2%
Return on invested capital
-27.4%
Return on capital employed
-17.5%
Return on sales
-51%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXAS stock price

How has the Exact Sciences stock price performed over time
Intraday
-2.83%
1 week
-7.52%
1 month
-14.9%
1 year
51.38%
YTD
-1.12%
QTD
-1.12%

Financial performance

How have Exact Sciences's revenue and profit performed over time
Revenue
$1.49B
Gross profit
$1.14B
Operating income
-$768.02M
Net income
-$848.53M
Gross margin
76.2%
Net margin
-56.9%
The company's net income has shrunk by 154% QoQ
The company's net margin has shrunk by 125% QoQ
The operating margin has dropped by 93% year-on-year and by 51% since the previous quarter
EXAS's gross profit has surged by 72% year-on-year and by 14% since the previous quarter

Growth

What is Exact Sciences's growth rate over time

Valuation

What is Exact Sciences stock price valuation
P/E
N/A
P/B
6.98
P/S
13.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.01
Exact Sciences's EPS has plunged by 163% from the previous quarter
The stock's price to book (P/B) is 27% more than its last 4 quarters average of 5.5 but 20% less than its 5-year quarterly average of 8.7
The company's equity rose by 23% YoY and by 21% QoQ
EXAS's revenue has surged by 70% year-on-year and by 13% since the previous quarter
EXAS's price to sales (P/S) is 26% less than its 5-year quarterly average of 18.0 but 19% more than its last 4 quarters average of 11.2

Efficiency

How efficient is Exact Sciences business performance
The ROE has plunged by 141% from the previous quarter
EXAS's return on assets has dropped by 133% since the previous quarter
The company's return on invested capital has shrunk by 119% YoY and by 60% QoQ
Exact Sciences's ROS has plunged by 115% YoY and by 53% from the previous quarter

Dividends

What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXAS.

Financial health

How did Exact Sciences financials performed over time
The total assets is 134% more than the total liabilities
The company's quick ratio has surged by 88% YoY but it fell by 39% QoQ
The total liabilities has surged by 73% year-on-year and by 4.2% since the previous quarter
The company's debt is 39% lower than its equity
EXAS's debt to equity is up by 45% year-on-year but it is down by 16% since the previous quarter
The company's equity rose by 23% YoY and by 21% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.